Home > Publications database > HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. > print

001     136828
005     20240229105101.0
024 7 _ |a 10.1158/0008-5472.CAN-17-2900
|2 doi
024 7 _ |a pmid:29735552
|2 pmid
024 7 _ |a pmc:PMC6065509
|2 pmc
024 7 _ |a 0008-5472
|2 ISSN
024 7 _ |a 0099-7013
|2 ISSN
024 7 _ |a 0099-7374
|2 ISSN
024 7 _ |a 1538-7445
|2 ISSN
024 7 _ |a altmetric:41165650
|2 altmetric
037 _ _ |a DKFZ-2018-01266
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Wang, Sophia S
|b 0
245 _ _ |a HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes.
260 _ _ |a Philadelphia, Pa.
|c 2018
|b AACR
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1536232510_3592
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a A growing number of loci within the human leukocyte antigen (HLA) region have been implicated in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of 'heterozygote advantage' regarding the role of HLA and NHL, whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk. HLA alleles at class I and II loci were imputed from genome-wide association studies (GWAS) using SNP2HLA for 3,617 diffuse large B-cell lymphomas (DLBCL), 2,686 follicular lymphomas (FL), 2,878 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 741 marginal zone lymphomas (MZL), and 8,753 controls of European descent. Both DLBCL and MZL risk were elevated with homozygosity at class I HLA-B and -C loci (OR DLBCL = 1.31, 95% CI = 1.06-1.60; OR MZL = 1.45, 95% CI = 1.12-1.89) and class II HLA-DRB1 locus (OR DLBCL = 2.10, 95% CI = 1.24-3.55; OR MZL = 2.10, 95% CI = 0.99-4.45). Increased FL risk was observed with the overall increase in number of homozygous HLA class II loci (P trend < 0.0001, FDR = 0.0005). These results support a role for HLA zygosity in NHL etiology and suggests that distinct immune pathways may underly the etiology of the different NHL subtypes.Significance: HLA gene diversity reduces risk for non-Hodgkin lymphoma. Cancer Res; 78(14); 4086-96. ©2018 AACR.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Carrington, Mary
|b 1
700 1 _ |a Berndt, Sonja I
|b 2
700 1 _ |a Slager, Susan L
|b 3
700 1 _ |a Bracci, Paige M
|b 4
700 1 _ |a Voutsinas, Jenna
|b 5
700 1 _ |a Cerhan, James R
|b 6
700 1 _ |a Smedby, Karin E
|b 7
700 1 _ |a Hjalgrim, Henrik
|b 8
700 1 _ |a Vijai, Joseph
|b 9
700 1 _ |a Morton, Lindsay M
|b 10
700 1 _ |a Vermeulen, Roel
|b 11
700 1 _ |a Paltiel, Ora
|b 12
700 1 _ |a Vajdic, Claire M
|b 13
700 1 _ |a Linet, Martha S
|b 14
700 1 _ |a Nieters, Alexandra
|b 15
700 1 _ |a de Sanjose, Silvia
|b 16
700 1 _ |a Cozen, Wendy
|b 17
700 1 _ |a Brown, Elizabeth E
|b 18
700 1 _ |a Turner, Jennifer
|0 0000-0001-5550-3375
|b 19
700 1 _ |a Spinelli, John J
|b 20
700 1 _ |a Zheng, Tongzhang
|b 21
700 1 _ |a Birmann, Brenda M
|b 22
700 1 _ |a Flowers, Christopher R
|b 23
700 1 _ |a Becker, Nikolaus
|0 P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab
|b 24
|u dkfz
700 1 _ |a Holly, Elizabeth A
|b 25
700 1 _ |a Kane, Eleanor
|b 26
700 1 _ |a Weisenburger, Dennis
|b 27
700 1 _ |a Maynadie, Marc
|b 28
700 1 _ |a Cocco, Pierluigi
|b 29
700 1 _ |a Albanes, Demetrius
|b 30
700 1 _ |a Weinstein, Stephanie J
|0 0000-0002-3834-1535
|b 31
700 1 _ |a Teras, Lauren R
|b 32
700 1 _ |a Diver, W Ryan
|b 33
700 1 _ |a Lax, Stephanie J
|b 34
700 1 _ |a Travis, Ruth C
|b 35
700 1 _ |a Kaaks, Rudolph
|0 P:(DE-HGF)0
|b 36
700 1 _ |a Riboli, Elio
|b 37
700 1 _ |a Benavente, Yolanda
|b 38
700 1 _ |a Brennan, Paul
|b 39
700 1 _ |a McKay, James
|b 40
700 1 _ |a Delfau-Larue, Marie-Hélène
|b 41
700 1 _ |a Link, Brian K
|b 42
700 1 _ |a Magnani, Corrado
|b 43
700 1 _ |a Ennas, Maria Grazia
|b 44
700 1 _ |a Latte, Giancarlo
|b 45
700 1 _ |a Feldman, Andrew L
|b 46
700 1 _ |a Doo, Nicole Wong
|b 47
700 1 _ |a Giles, Graham G
|b 48
700 1 _ |a Southey, Melissa C
|b 49
700 1 _ |a Milne, Roger L
|b 50
700 1 _ |a Offit, Kenneth
|b 51
700 1 _ |a Musinsky, Jacob
|b 52
700 1 _ |a Arslan, Alan A
|b 53
700 1 _ |a Purdue, Mark P
|b 54
700 1 _ |a Adami, Hans-Olov
|b 55
700 1 _ |a Melbye, Mads
|b 56
700 1 _ |a Glimelius, Bengt
|b 57
700 1 _ |a Conde, Lucia
|b 58
700 1 _ |a Camp, Nicola J
|b 59
700 1 _ |a Glenn, Martha
|b 60
700 1 _ |a Curtin, Karen
|b 61
700 1 _ |a Clavel, Jacqueline
|b 62
700 1 _ |a Monnereau, Alain
|b 63
700 1 _ |a Cox, David G
|b 64
700 1 _ |a Ghesquières, Hervé
|b 65
700 1 _ |a Salles, Gilles
|b 66
700 1 _ |a Bofetta, Paulo
|b 67
700 1 _ |a Foretova, Lenka
|b 68
700 1 _ |a Staines, Anthony
|b 69
700 1 _ |a Davis, Scott
|b 70
700 1 _ |a Severson, Richard K
|b 71
700 1 _ |a Lan, Qing
|b 72
700 1 _ |a Brooks-Wilson, Angela
|b 73
700 1 _ |a Smith, Martyn T
|b 74
700 1 _ |a Roman, Eve
|b 75
700 1 _ |a Kricker, Anne
|b 76
700 1 _ |a Zhang, Yawei
|b 77
700 1 _ |a Kraft, Peter
|b 78
700 1 _ |a Chanock, Stephen J
|b 79
700 1 _ |a Rothman, Nathaniel
|b 80
700 1 _ |a Hartge, Patricia
|b 81
700 1 _ |a Skibola, Christine F
|b 82
773 _ _ |a 10.1158/0008-5472.CAN-17-2900
|g Vol. 78, no. 14, p. 4086 - 4096
|0 PERI:(DE-600)2036785-5
|n 14
|p 4086 - 4096
|t Cancer research
|v 78
|y 2018
|x 1538-7445
909 C O |o oai:inrepo02.dkfz.de:136828
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 36
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2018
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER RES : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCER RES : 2015
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebserkrankungen
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21